Preterm Delivery Clinical Trial
Official title:
Serum Levels of Hormones Known to Affect Parturition in Patients Receiving 17 Alpha-Hydroxyprogesterone Caproate (17-P) for the Prevention of Preterm Delivery
The purpose of this study is to measure hormones in the blood known to affect the timing of delivery after a single injection of 17-P in order to help understand its mechanism of action in preventing preterm delivery.
A recent study by Meis and colleagues published in the New England Journal of Medicine in
June 2003 demonstrated a 33% reduction in the rate of preterm delivery in patients with a
previous history of preterm delivery who then used weekly 17-P injections in the subsequent
pregnancy.
This is a milestone in the prevention of preterm delivery and is the reason you have chosen
to receive treatment with 17-P.
However, how 17-P works to prevent preterm delivery is unclear. Knowledge of the mechanism
of action of 17-P would help in selecting patients for treatment and may be useful in
monitoring the efficacy of therapy.
Studies have suggested that the timing of delivery depends on a type of placental clock,
affected by levels of corticotropin-releasing hormone (CRH) and progesterone (P).
CRH can be thought to act as an accelerator, and P as a brake. Serial injections of 17-P
beginning in the second trimester of pregnancy may prevent preterm delivery by maintaining
progesterone dominance, and be reflected in increased levels of progesterone and/or 17-P, or
decreased levels of cortisol and/or CRH. These are the hormones that will be measured in
this study.
Results of the study will be important whatever the outcome. If there is no measurable
change in the hormones measured, this is important to know and investigation of other
markers can be pursued. If there is a measurable change in the hormones measured, then this
pilot study could serve to support a larger more definitive study, which could lead to very
valuable information relating to the practical use of 17-P for the prevention of preterm
delivery.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03304782 -
Fitbit Activity Tracker to Predict Risk of Preterm Birth
|
||
| Recruiting |
NCT02420743 -
Serum Ferritin Concentration and Fetal MCA Doppler as Predictors for Preterm Delivery
|
||
| Completed |
NCT01665378 -
Impact of Pre-pregnancy Micronutrient Supplementation on Maternal and Child Outcomes
|
N/A | |
| Completed |
NCT01119963 -
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
|
Phase 2/Phase 3 | |
| Completed |
NCT00141908 -
Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate
|
Phase 2 | |
| Recruiting |
NCT05278130 -
Serial Screening and Treatment of Bacterial Vaginosis Trial
|
N/A | |
| Terminated |
NCT03596125 -
Correction of Neonatal Glutathione by N-acetylcysteine in Pregnant Women at Risk of Premature Birth (GSH MAP)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03123926 -
Spontaneous Preterm Birth Marker Test
|
N/A | |
| Completed |
NCT00201643 -
A Randomized Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids (ACS) on Neonatal Outcome
|
Phase 4 | |
| Completed |
NCT01353807 -
Impact of Fish Oil Supplementation in 3rd Trimester of Pregnancy on Maternal and Offspring Health
|
N/A | |
| Terminated |
NCT02545127 -
Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely
|
Phase 2 | |
| Completed |
NCT02371356 -
Comparing Effectiveness of Treating Depression With & Without Comorbidity to Improve Fetal Health
|
||
| Active, not recruiting |
NCT01009723 -
Preterm Delivery Risk Prediction by Measurement of Prenatal Serum Screening Markers
|
N/A | |
| Completed |
NCT00883324 -
Comparison of Fetal Fibronectin (fFN) Specimen Collection Methodologies: With Speculum Versus Without Speculum
|
N/A | |
| Completed |
NCT00615550 -
PREGNANT Short Cervix Trial
|
Phase 3 | |
| Completed |
NCT02694679 -
Randomized Controlled Trial of Social Network Targeting in Honduras
|
N/A | |
| Completed |
NCT01031017 -
Prophylactic Administration of Natural Progesterone in the Prevention of Preterm Delivery in Twin Pregnancies
|
Phase 4 | |
| Completed |
NCT00331695 -
Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery
|
Phase 4 | |
| Completed |
NCT00329914 -
Does Progesterone Prevent Very Preterm Delivery in Twin Pregnancies?
|
Phase 2 | |
| Completed |
NCT01818518 -
Neonatal Outcome by Reason for Delivery
|